Uterine sarcoma is a rare cancer that develops in the muscle or connective tissue of the uterus, rather than in the uterine lining where most uterine cancers begin. It accounts for only 2% to 5% of all uterine cancers, but it tends to be more aggressive and harder to detect early than the more common endometrial cancers.
How It Differs From Other Uterine Cancers
The most common type of uterine cancer, endometrial carcinoma, starts in the layer of cells lining the inside of the uterus. Uterine sarcoma is fundamentally different. It arises from the supportive tissues of the uterus: the smooth muscle that makes up the uterine wall or the connective tissue (stroma) that sits beneath the lining. Because these tumors grow within the wall of the uterus rather than on its surface, they’re harder to detect through routine screening and biopsies. They also tend to behave more aggressively, with higher rates of recurrence and spread to distant organs.
The Main Subtypes
Uterine sarcomas fall into several categories, each with distinct behavior and outlook.
Leiomyosarcoma is by far the most common subtype, making up roughly 70% of cases. It develops from the smooth muscle of the uterine wall, the same tissue that gives rise to fibroids (which are benign). Leiomyosarcoma typically appears in women between ages 50 and 55. It carries a poor prognosis overall, with a high risk of recurrence and spread even after treatment.
Endometrial stromal sarcoma (ESS) accounts for about 25% of cases and develops from the connective tissue just below the uterine lining. It tends to occur earlier, usually in premenopausal women in their 40s. ESS comes in two forms. Low-grade ESS grows slowly and often responds well to hormone-blocking therapy, giving it a much more favorable outlook. High-grade ESS is far rarer and more aggressive; it does not respond to hormonal treatment and is typically treated with chemotherapy, though results are often limited.
Adenosarcoma is an uncommon subtype that contains both glandular and sarcomatous tissue. It generally has a better prognosis than leiomyosarcoma, though cases with deep invasion into the uterine wall are more concerning.
Symptoms to Recognize
The symptoms of uterine sarcoma overlap heavily with common, noncancerous conditions like fibroids, which is one reason diagnosis is so often delayed. The most frequent signs are abnormal vaginal bleeding (reported in about 56% of leiomyosarcoma cases), a palpable pelvic mass (54%), and pelvic pain (22%). Some women also experience painful periods or unusual vaginal discharge.
Endometrial stromal sarcoma can be even more subtle. As many as 25% of women with ESS have no symptoms at all, with the tumor discovered incidentally during surgery for another reason. A pelvic mass that seems to be growing rapidly is sometimes flagged as suspicious, though defining “rapid growth” remains a point of debate among specialists. In rare cases, a leiomyosarcoma can rupture and cause internal bleeding.
Why It’s So Hard to Diagnose Before Surgery
One of the most frustrating aspects of uterine sarcoma is that there is no reliable way to distinguish it from a benign fibroid before surgery. On ultrasound, the two can look nearly identical. Lab tests and imaging overlap significantly between sarcomas and fibroids, and many sarcomas are only identified after a uterus or mass has been surgically removed and examined under a microscope. Pathology remains the gold standard for diagnosis.
MRI is the best imaging tool available for raising suspicion. Certain features on MRI can hint at sarcoma: irregular tumor borders, areas of internal bleeding or tissue death, and patterns of blood flow that differ from typical fibroids. When ultrasound raises concern about a potentially malignant uterine mass, MRI is the recommended next step. Even so, some types of degenerating fibroids mimic sarcoma on MRI, leading to a meaningful rate of misdiagnosis in both directions.
Preoperative biopsy is technically possible but comes with limitations. It requires a high degree of skill, and there’s a risk of inadequate sampling (missing the cancerous tissue entirely) or, rarely, seeding cancer cells. During surgery, a rapid frozen-section analysis of tissue can sometimes help guide the extent of the operation in real time.
Known Risk Factors
Most uterine sarcomas arise without a clearly identifiable cause, but a few risk factors have been established. Prior pelvic radiation increases risk. Tamoxifen, a drug widely used to treat and prevent breast cancer, was already known to raise the risk of endometrial carcinoma. The FDA later added a warning that tamoxifen also increases the risk of uterine sarcoma specifically. Among women taking tamoxifen, the estimated rate is about 0.17 per 1,000 women per year, compared with 0.01 to 0.02 per 1,000 in women not taking the drug. While the absolute risk remains small, it represents roughly a tenfold increase.
Staging and Survival
Uterine sarcoma is staged using the FIGO system, which categorizes the cancer based on how far it has spread. For leiomyosarcoma and endometrial stromal sarcoma, staging is based primarily on tumor size and whether it has moved beyond the uterus:
- Stage I: Tumor confined to the uterus (IA if 5 cm or smaller, IB if larger)
- Stage II: Tumor extends into the pelvis beyond the uterus
- Stage III: Tumor invades abdominal tissues or has reached pelvic or abdominal lymph nodes
- Stage IV: Tumor has invaded the bladder or rectum, or has spread to distant sites
The survival outlook depends heavily on stage at diagnosis. Women with stage I disease, where the tumor is still confined to the uterus, have an approximate 5-year survival rate of 50%. For stages II through IV, that rate drops to between 0% and 20%. This stark difference underscores why early detection, though difficult, matters enormously.
Treatment Approach
Surgery is the primary treatment for all types of uterine sarcoma. The standard operation is a hysterectomy, often with removal of the ovaries and fallopian tubes. The goal is to remove the entire tumor with clear margins. For leiomyosarcoma in particular, complete surgical removal offers the best chance of long-term control, though recurrence rates remain high.
What happens after surgery depends on the subtype. Low-grade endometrial stromal sarcoma is one of the few subtypes that responds to hormonal therapy. These tumors carry high levels of estrogen and progesterone receptors, sometimes even higher than normal uterine tissue. Blocking estrogen with hormone-suppressing medications can slow or prevent recurrence. For this reason, testing the tumor for hormone receptor status is an important part of planning treatment.
High-grade tumors and leiomyosarcoma generally do not respond well to hormone therapy. Chemotherapy and sometimes radiation are used, particularly for advanced or recurrent disease, but their effectiveness is limited. Radiation may help reduce the chance of the cancer returning in the pelvis, though it has not been shown to improve overall survival for most subtypes.
Monitoring After Treatment
Because uterine sarcomas carry a significant risk of recurrence, follow-up care after treatment is structured and ongoing. About 75% of recurrences happen within the first two to three years after diagnosis. Physical exams including pelvic exams are typically recommended every three to six months for the first two years, then every six to twelve months thereafter, with the schedule adjusted based on individual risk.
For women at lower risk, imaging is generally reserved for those who develop new symptoms or have abnormal findings on exam. For higher-risk patients, some degree of imaging in the first two years is common, though the ideal frequency is still being refined. Paying attention to new or returning symptoms, particularly pelvic pain, vaginal bleeding, or shortness of breath (which could signal spread to the lungs, a common site for leiomyosarcoma metastasis), is an important part of long-term surveillance.